Digitized | Featured #78
Welcome to this week's edition of Featured, your weekly guide to the most interesting blockchain-based digital objects – across gaming, social, music, media, fashion, AI, immersive environments, and other consumer crypto categories.
This week, we turn the spotlight on REKTECH, a new and experimental consumer crypto project disguised as an AI pharmaceutical company.
Just last week, REKTECH launched their Degen Simulator–a game that satirized the memecoin trading craze. Players received a virtual $1,000 to “invest” in memecoins with the aim of taking profits and dodging rug pulls.
The game, which has since ended, was played 250K+ times.
Top players of this game can look forward to real memecoin rewards + exclusive access to REKTECH’s next project phase: a unique “clinical trial” experience.
Guiding players through the experience was Hana, REKTECH’s AI Clinical Researcher. You can expect to see more of Hana as REKTECH rolls out new experiments. Follow her here.
The Degen Simulator was just a teaser. REKTECH is hinting at bigger plans ahead. Collect as much XP as you can in their upcoming activations.
This content is educational in nature and is not investment advice.
If you enjoyed this edition of Featured, please subscribe below and follow @digitizedweekly on Twitter.
Collab+Currency may be an investor in the projects and/or products that appear in Featured.
Information regarding any company or investment in Featured should not be construed as an endorsement or recommendation of that company or investment for any purpose whatsoever, either for purposes of investment or otherwise. Any person receiving Featured or accessing our website is encouraged to consult with their own financial advisor, tax advisor and/or attorney before making any decision to invest.
The above material and content is educational in nature and should not be considered to be a recommendation to invest. Investing in digital assets, NFTs or cryptocurrency is highly speculative and volatile. Past performance is not indicative of future results.